STOCK TITAN
  1. Home
  2. News
  3. VYGR

Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report fourth quarter and full year 2020 financial results after market close on Thursday, February 25, 2021. Subsequently, at 4:30 p.m. EST, the Company will host a live conference call and webcast to discuss its financial results and provide a corporate update.

The conference call may be accessed by dialing (877) 851-3834 for domestic callers, or +1 (631) 291-4595 for international callers. Please reference conference ID number 3688928 to join the call. The conference call will be webcast live from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com and will be archived there following the call for 90 days.

Additionally, the company will participate in a panel discussion at the Cowen 41st Annual Health Care Conference on Monday, March 1, 2021 at 11:40 a.m. EST.

The webcast session may be accessed from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. Replays of the webcast will be archived on the Company's website for at least 30 days.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager’s wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson’s disease, Huntington’s disease, Friedreich’s ataxia, and other severe neurological diseases. For more information on Voyager Therapeutics, please visit the company’s website at www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn.

Investors:

Investors@voyagertherapeutics.com

Media:

Sheryl Seapy
W2Opure
949-903-4750
sseapy@purecommunications.com


Stock VYGR logo
Voyager Therapeutics, Inc.

NASDAQ:VYGR

VYGR Rankings

#3080 Ranked by Market Cap
#801 Ranked by Stock Gains
N/A Ranked by Dividends

VYGR Latest News

May 8, 2024
Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
May 6, 2024
Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Apr 22, 2024
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
Apr 16, 2024
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Mar 26, 2024
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VYGR Stock Data

459.04M
36.94M
17.29%
49%
6.13%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
LEXINGTON

About VYGR

voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.